4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

← catalyst calendar

NCT05197270 · readout ≤ 224 d

Sponsored by 4D Molecular Therapeutics (industry) · FDMT — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Randomized · Single · Treatment

Enrollment

215estimated

Sites

Countries

Puerto Rico, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2021-12-09

actual

When the study began enrolling

Primary completion

Mar 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jan 2031

estimated

The whole study's end, after follow-up

First posted

2022-01-19

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-02-12

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Neovascular (Wet) Age-Related Macular Degeneration

Interventions

Biological: 4D-150 IVT
Biological: Aflibercept IVT

Primary outcome

what the primary-completion date above is the date OF

Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically significant changes in safety parameters

measured 52 weeks

Publications

PMID 39620832 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · FDMT's whole pipeline · Catalyst calendar · Every registered study · What changed